Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov-Dec;10(11-12Suppl7):S256-S258.
doi: 10.5489/cuaj.4294.

The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma

Daniel Y C Heng  1
Affiliations
Review

The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma

Daniel Y C Heng. Can Urol Assoc J. 2016 Nov-Dec.

Abstract

The introduction of targeted therapies over the past 10 years revolutionized the treatment of metastatic renal cell carcinoma (mRCC). The next 10 years hold promise for even greater expansion of the therapeutic armamentarium for mRCC. A number of recently completed and ongoing trials have explored the use of antivascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors in the adjuvant setting, the use of predictive biomarkers to guide personalized medicine, as well as new systemic treatments and combination therapies for mRCC.

PubMed Disclaimer

References

    1. Janowitz T, Welsh SJ, Zaki K, et al. Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol. 2013;40:482–91. https://doi.org/10.1053/j.seminoncol.2013.05.004. - DOI - PMC - PubMed
    1. Haas NB, Manola J, Ky B, et al. Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res. 2015;21:4048–54. https://doi.org/10.1158/1078-0432.CCR-15-0215. - DOI - PMC - PubMed
    1. Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal cell carcinoma after nephrectomy. N Engl J Med. 2016 (Epub before print) - PubMed
    1. Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localized renal cell carcinoma: Development and validation studies. Lancet Oncol. 2015;16:676–85. https://doi.org/10.1016/S1470-2045(15)70167-1. - DOI - PubMed
    1. Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016;22:2445–52. https://doi.org/10.1158/1078-0432.CCR-15-2631. - DOI - PMC - PubMed

LinkOut - more resources